Short-term Therapeutic Outcomes of Robotic-Assisted Laparoscopic Radical Prostatectomy for Oligometastatic Prostate Cancer: A Propensity Score Matching Study
Prostate cancer is the second leading cause of cancer-related death in men in the U.S.—and in China, many patients are diagnosed at an advanced stage with metastases. For decades, androgen deprivation therapy (ADT) has been the mainstay for metastatic prostate cancer (mPCa). But a growing body of research suggests local treatment—like surgery—might help even when cancer has spread a little (called oligometastatic prostate cancer, or OPC). Now, a study from Shanghai’s Changhai Hospital offers new insights into whether robotic-assisted surgery is safe and effective for these patients.
What Is Oligometastatic Prostate Cancer?
Oligometastatic prostate cancer (OPC) is an intermediate stage between localized cancer (confined to the prostate) and widespread metastatic disease. The study defined it as 2 or fewer suspicious lesions (detected via bone scans, PET/CT, or MRI) with no spread to organs like the lungs or liver. Unlike patients with extensive metastases, those with OPC may benefit from targeting both the primary tumor and limited spread—a idea first proposed by researchers Hellman and Weichselbaum in 1995.
The Study: Robotic Surgery for OPC vs. Localized Cancer
Researchers led by Huan Chen and Min Qu (from Changhai Hospital and the Second Military Medical University) analyzed 508 consecutive patients who underwent robotic-assisted laparoscopic radical prostatectomy (RALP)—a minimally invasive surgery to remove the prostate—as first-line treatment between 2012 and 2017. Of these, 41 had OPC, and 467 had localized prostate cancer.
To make the groups comparable (and reduce bias from factors like age or tumor stage), the team used propensity score matching—a statistical tool that pairs patients with similar characteristics (e.g., PSA levels, Gleason score, tumor stage). This resulted in 41 matched pairs: 41 OPC patients and 41 localized cancer patients with nearly identical backgrounds.
The team tracked key outcomes:
- Peri-operative stats: Operative time, blood loss, hospital stay, and positive surgical margins (PSM—when cancer cells are left on the edge of the removed tissue).
- Quality of life: Urinary continence (measured by using 0 or 1 pad daily, a critical factor after prostate surgery).
- Survival: Biochemical recurrence (BCR—when PSA levels rise again, a sign of cancer return) and overall survival (OS).
What Did They Find?
The results were surprising: OPC patients had nearly identical outcomes to those with localized cancer—even after surgery. Here’s the breakdown:
1. Peri-Operative Safety Was Similar
- Operative time: Median 140 minutes for OPC vs. 130 minutes for localized (no significant difference).
- Blood loss: Median 160 mL vs. 150 mL (both low for prostate surgery).
- Hospital stay: 6 days for both groups.
- Complications: Only minor issues—one OPC patient had prolonged pelvic drainage, and one localized patient had temporary urinary retention (fixed with medication).
- Positive surgical margins: 36.6% for both groups (a common metric of surgical success).
2. Urinary Continence Recovered Well for Both Groups
Urinary continence is a top concern for prostate surgery patients. The 12-month “pad-free” rate was 93.8% for OPC and 82.3% for localized cancer—no significant difference. By the one-year mark, almost all patients in both groups were continent.
3. Survival Outcomes Were Comparable
- 1-month PSA decline: 95.4% for OPC vs. 97.0% for localized (PSA drop is a sign the surgery worked).
- 4-year BCR-free survival: 56.7% for OPC vs. 60.8% for localized (no statistically significant difference).
- 5-year overall survival: 96.3% for OPC vs. 100% for localized (only one OPC patient died from prostate cancer during follow-up).
Importantly, oligometastatic status wasn’t an independent risk factor for recurrence. The real drivers of BCR were:
- High pre-operative PSA (over 20 ng/mL),
- Aggressive tumor grade (Gleason score >7),
- Advanced tumor stage (T3a or higher).
What Does This Mean for Patients?
These findings add to growing evidence that RALP is a safe, effective option for carefully selected OPC patients. For years, doctors assumed metastatic prostate cancer was “untreatable” with surgery—but the oligometastases hypothesis suggests targeting limited spread could slow progression.
The study builds on work from researchers like Gandaglia et al., who found radical prostatectomy (with other treatments) improved outcomes for mPCa patients. And it aligns with Jang et al.’s 2018 study, which linked RALP to better progression-free survival in OPC.
But the key word here is “selected”. The OPC patients in this study had only 1–2 bone lesions (no organ spread), and the surgery was done by an experienced team. This isn’t a green light for all metastatic prostate cancer patients—just those with very limited spread.
Limitations and Next Steps
Like all studies, this one has caveats:
- Short follow-up: Median follow-up was 26.4 months for OPC (18.3 months for localized). Longer data is needed to confirm long-term survival.
- Retrospective design: The study looked back at past patients, which can introduce bias (even with propensity matching). A prospective trial (where patients are assigned to treatments in advance) would be stronger.
- No ADT control group: The study didn’t compare RALP to ADT (the standard for mPCa). We don’t know if surgery is better than hormone therapy alone.
The authors plan to address these gaps with future clinical trials—critical steps to validate their findings.
Conclusion
For men with oligometastatic prostate cancer (limited to 2 bone lesions, no organ spread), robotic-assisted radical prostatectomy (RALP) appears to be safe, effective, and comparable to outcomes in localized cancer. The study suggests that oligometastatic status alone doesn’t make surgery riskier—and that factors like PSA, Gleason score, and tumor stage are more important for predicting recurrence.
This is hopeful news for patients facing advanced prostate cancer: even when cancer has spread a little, local treatment might still offer a path to better survival and quality of life.
The original study was published in the Chinese Medical Journal in 2020 by Huan Chen, Min Qu, and colleagues from Changhai Hospital and the Second Military Medical University.
doi.org/10.1097/CM9.0000000000000590
Was this helpful?
0 / 0